Business Context and Reporting Period
Company: Aardvark Therapeutics, Inc. (AARD)
Filing Type: Form 8-K (Current Report)
Date of Report: February 10, 2026
Reporting Period: Single event date (February 10, 2026)
The Company is a biopharmaceutical firm focused on developing treatments for Prader-Willi Syndrome. This filing reports a specific regulatory milestone regarding its lead candidate, ARD-101.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements, revenue data, profit figures, cash flow, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial indicators.
Material Changes
The material change reported is a regulatory and clinical development update:
- Event: Institutional Review Board (IRB) approval granted in the United States for an amended protocol to the ongoing Phase 3 HERO pivotal clinical trial.
- Subject: Evaluation of ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome.
- Protocol Amendment: The minimum age of eligibility for participation in the trial has been lowered from ten years old to seven years old.
- Regulatory Status: The amended protocol has been submitted to the U.S. Food and Drug Administration (FDA).
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) announcing the IRB approval. No specific financial guidance or forward-looking revenue projections are included in this document.
Risks and Contingencies: While the filing does not explicitly list new risks, the success of the Phase 3 HERO trial remains contingent on the successful execution of the amended protocol and continued regulatory compliance. The lowering of the age eligibility introduces a new pediatric cohort, which may carry distinct clinical and regulatory considerations.
Investor Verification Checklist
- Verify the full text of the press release filed as Exhibit 99.1 for additional details on the trial design.
- Confirm the timeline for the first patient enrollment under the amended protocol (ages 7-10).
- Monitor subsequent filings for FDA feedback on the submitted amended protocol.
- Review the Company's most recent 10-K or 10-Q for current cash runway and burn rate, as this 8-K contains no financial data.